Galecto Biotech AB develops drugs for the treatment of fibrosis, inflammation, and other serious human diseases. The Company offers a series of galectin modulators for the treatment of severe

Director CMC, Drug Substance. Göteborg. Galecto Biotech. Vill du se dina favoritannonser? Klicka här. Director CMC, Drug Product. Göteborg. Galecto Biotech.

The company lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, in which there is high unmet medical Galecto Biotech develops small molecules for the treatment of severe diseases. The company, founded in 2011, builds on more than 10 years of research and the use of galectin modulators to treat fibrosis-related diseases and cancer. Galecto Biotech AB - Org.nummer: 5568728413. Fördelningen i styrelsen är 100,0 % män (1), 0,0 % kvinnor (0) .

Galecto biotech

Göteborg. Galecto Biotech. Vill du se dina favoritannonser? Klicka här. Director CMC, Drug Product. Göteborg.

The company builds on more than 10 years of research into galectins and galectin modulators, which combined with a strong patent estate gives Galecto Biotech a unique platform. Galecto Biotech. PhD FRSB.

Galecto Biotech develops small molecules for the treatment of severe diseases. The company, founded in 2011, builds on more than 10 years of research and the use of galectin modulators to treat fibrosis-related diseases and cancer.

We offer in vitro 9 Jan 2020 Galecto Biotech, a Denmark-based cancer and fibrosis treatment developer backed by pharmaceutical firms Bristol Myers-Squibb (BMS), Novo 26 Oct 2018 Galecto Biotech AB has completed a EUR 79 million Series C financing co-led by Ysios Capital and OrbiMed. The proceeds will be used to 9 Sep 2016 Kent Hoover, Isabel Lippincott, Angel Pichardo, Katherine Anne Rebholz, Beau Smith, Katrina Wiesner Galecto Biotech. 2 Nov 2014 Bristol-Myers Squibb entered into an agreement with Galecto Biotech AB to gain exclusive rights to TD139, a novel inhaled inhibitor of Galecto is a Swedish company founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. Galecto Biotech AB,556872-8413 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status, adress mm för Galecto Biotech AB. Galecto Biotech AB,556872-8413 - På allabolag.se hittar du , bokslut, nyckeltal, koncern, koncernträd, styrelse, Status.

Danmark 28 oktober, 2018 Galecto Biotech tar in 79 miljoner euro i nytt kapital Danska bioteknikföretaget Galecto Biotech med lokaler på Copenhagen Bio

The idiopathic pulmonary fibrosis (IPF) market was valued at $2.5 billion in 2019 Galecto Biotech is a biotech company with offices in Copenhagen, London, Montreal, Gothenburg, Edinburgh and Boston. Galecto Biotech develops galectin Galecto Biotech is a Swedish private biotechnology company that has developed a galectin-3 inhibitor that would prevent fibrosis.

Galecto Biotech utvecklar nya läkemedel mot fibros. Preparatet ska med hjälp av en särskild slags proteiner stoppa ärrbildningarna som sjukdomen medför. Fibros kan drabba flera olika organ. Galecto, Inc. | 1,531 followers on LinkedIn.
Grammar police

Galecto Biotech develops new therapies for fibrotic diseases and inflammation based on inhibition of Galectins. The Company is based on seminal research from Lund University, Sweden, exploring the role of a group of proteins called Galectins. Galecto develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these … Galecto Biotech.

The company builds on more than 10 years of research GALECTO BIOTECH AB OLE MAALOES VEJ3. COPENHAGEN G7 DK-2200. Business Phone, 45-70-70-52-10. Mailing Address.
Anteciperad utdelning koncernredovisning

Bakgrunden till företagen är en uppfinning av en ny process för År 2011 startades företaget Galecto Biotech med syfte. Lesen Sie das gleiche:

Date of investment November 2011 . Website Visit their website. Galecto focuses on developing novel drugs for the treatment of fibrosis, inflammation and other serious human diseases. Contact person. Søren Møller, Managing Partner. Go to Hans has co-founded several biotech companies, including ProFound Pharma A/S, a Danish biotech company, Anders Pedersen has served as Chief Operating Officer of the Galecto group since April 2013, including as Chief Operating Officer of Galecto, Inc. since 2020. Om Galecto Biotech AB. Galecto Biotech AB är verksam inom annan naturvetenskaplig och teknisk forskning och utveckling och hade totalt 1 anställd 2019.

Eir Ventures co-leads high profile syndicate in €55 million investment in Galecto Biotech Eir Ventures will appoint Stephan Christgau to the Galecto board.

Galecto. Galecto is a Swedish company founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark.

Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmar k. Galecto Biotech AB. Galecto Biotech AB is a Swedish company founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark.